12:06 PM EST - ProMIS Neurosciences, Inc. : Has designated PMN330, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AßO), as its third lead product for development in Alzheimer's disease. ProMIS Neurosciences, Inc.
shares T.PMN are trading up $0.005 at $0.21.
